LT3906927T - Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti - Google Patents
Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydytiInfo
- Publication number
- LT3906927T LT3906927T LTEP20305429.1T LT20305429T LT3906927T LT 3906927 T LT3906927 T LT 3906927T LT 20305429 T LT20305429 T LT 20305429T LT 3906927 T LT3906927 T LT 3906927T
- Authority
- LT
- Lithuania
- Prior art keywords
- dopamine
- nervous system
- central nervous
- system disorders
- partial agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305429.1A EP3906927B1 (en) | 2020-05-04 | 2020-05-04 | Use of dopamine d3 partial agonists for treating central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3906927T true LT3906927T (lt) | 2022-08-10 |
Family
ID=70802820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP20305429.1T LT3906927T (lt) | 2020-05-04 | 2020-05-04 | Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230165852A1 (lt) |
| EP (2) | EP3906927B1 (lt) |
| JP (1) | JP2023523862A (lt) |
| KR (1) | KR20230005860A (lt) |
| CN (1) | CN115715195A (lt) |
| AU (1) | AU2021267681A1 (lt) |
| BR (1) | BR112022022317A2 (lt) |
| CA (1) | CA3176643A1 (lt) |
| DK (1) | DK3906927T3 (lt) |
| ES (1) | ES2925982T3 (lt) |
| HR (1) | HRP20220739T1 (lt) |
| HU (1) | HUE059092T2 (lt) |
| IL (1) | IL297706A (lt) |
| LT (1) | LT3906927T (lt) |
| PL (1) | PL3906927T3 (lt) |
| PT (1) | PT3906927T (lt) |
| RS (1) | RS63302B1 (lt) |
| SI (1) | SI3906927T1 (lt) |
| WO (1) | WO2021224235A1 (lt) |
| ZA (1) | ZA202211589B (lt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19938823A1 (de) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| EP1591455A1 (en) * | 2004-04-29 | 2005-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Essential tremor diagnostic and treatment |
| US8222266B2 (en) * | 2006-04-03 | 2012-07-17 | Glaxo Group Limited | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors |
| EP1870405A1 (en) * | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| CA2985370A1 (en) * | 2015-05-07 | 2016-11-10 | Axovant Sciences Gmbh | Compositions and methods of treating a neurodegenerative disease |
-
2020
- 2020-05-04 LT LTEP20305429.1T patent/LT3906927T/lt unknown
- 2020-05-04 RS RS20220566A patent/RS63302B1/sr unknown
- 2020-05-04 PL PL20305429.1T patent/PL3906927T3/pl unknown
- 2020-05-04 SI SI202030066T patent/SI3906927T1/sl unknown
- 2020-05-04 HR HRP20220739TT patent/HRP20220739T1/hr unknown
- 2020-05-04 DK DK20305429.1T patent/DK3906927T3/da active
- 2020-05-04 ES ES20305429T patent/ES2925982T3/es active Active
- 2020-05-04 PT PT203054291T patent/PT3906927T/pt unknown
- 2020-05-04 EP EP20305429.1A patent/EP3906927B1/en active Active
- 2020-05-04 HU HUE20305429A patent/HUE059092T2/hu unknown
-
2021
- 2021-05-04 US US17/922,767 patent/US20230165852A1/en active Pending
- 2021-05-04 CN CN202180032213.0A patent/CN115715195A/zh active Pending
- 2021-05-04 IL IL297706A patent/IL297706A/en unknown
- 2021-05-04 CA CA3176643A patent/CA3176643A1/en active Pending
- 2021-05-04 AU AU2021267681A patent/AU2021267681A1/en active Pending
- 2021-05-04 JP JP2022567115A patent/JP2023523862A/ja active Pending
- 2021-05-04 EP EP21722486.4A patent/EP4146214A1/en active Pending
- 2021-05-04 BR BR112022022317A patent/BR112022022317A2/pt unknown
- 2021-05-04 WO PCT/EP2021/061689 patent/WO2021224235A1/en active Application Filing
- 2021-05-04 KR KR1020227038661A patent/KR20230005860A/ko active Search and Examination
-
2022
- 2022-10-24 ZA ZA2022/11589A patent/ZA202211589B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3906927B1 (en) | 2022-05-25 |
| ZA202211589B (en) | 2023-04-26 |
| RS63302B1 (sr) | 2022-07-29 |
| IL297706A (en) | 2022-12-01 |
| PT3906927T (pt) | 2022-07-27 |
| DK3906927T3 (da) | 2022-06-20 |
| EP3906927A1 (en) | 2021-11-10 |
| US20230165852A1 (en) | 2023-06-01 |
| EP4146214A1 (en) | 2023-03-15 |
| KR20230005860A (ko) | 2023-01-10 |
| JP2023523862A (ja) | 2023-06-07 |
| WO2021224235A1 (en) | 2021-11-11 |
| CA3176643A1 (en) | 2021-11-11 |
| ES2925982T3 (es) | 2022-10-20 |
| CN115715195A (zh) | 2023-02-24 |
| PL3906927T3 (pl) | 2022-07-25 |
| SI3906927T1 (sl) | 2022-08-31 |
| AU2021267681A1 (en) | 2022-12-01 |
| HRP20220739T1 (hr) | 2022-08-19 |
| HUE059092T2 (hu) | 2022-10-28 |
| BR112022022317A2 (pt) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304429A (en) | Methods and preparations for the treatment of epileptic disorders | |
| EA201992474A2 (ru) | Агонисты 5ht для лечения нарушений | |
| EP4010072A4 (en) | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| IL295536A (en) | Specific tryptamines for use in the treatment of mood disorders | |
| MX2009012787A (es) | Nuevas fenilpirrolidinas disustituidas como moduladores de neurotransmision catecolaminergica cortical. | |
| EP3700525A4 (en) | IMPROVED PROVISION OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH OXIDATIVE STRESS | |
| EP4185382A4 (en) | METHODS FOR TREATING ACUTE RESPIRATORY DISEASES | |
| EP4048263A4 (en) | METHODS OF TREATING NEUROLOGICAL DISORDERS WITH PARTIAL ALPHA 1A-AR AGONISTS | |
| EP3618824A4 (en) | USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| IL288655A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| IL269179A (en) | Method for monitoring treatment of neuropsychiatric disorders | |
| IL283654A (en) | Decarboxylase inhibitors for the treatment of Parkinson's disease | |
| EP3694558A4 (en) | IL-4 FUSION FORMULATIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS | |
| ZA202211589B (en) | Use of dopamine d3 partial agonists for treating central nervous system disorders | |
| IL313097A (en) | Methods for treating central nervous system disorders | |
| GB201914034D0 (en) | Treatment of neurological disorders | |
| MX2009012716A (es) | Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. | |
| IL263494A (en) | Use of lithium benzoate to treat disorders of the central nervous system | |
| EP4229035A4 (en) | INTRANASAL ADMINISTRATION OF SURAMIN FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS | |
| SG10202101500WA (en) | PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS | |
| IL289221A (en) | Compounds for the treatment of vision disorders | |
| EP4228642A4 (en) | ADMINISTRATION OF ANTIPURINERGIC COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | |
| GEP20227402B (en) | Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines | |
| GB202109675D0 (en) | Treatment for tyrosine degradation-associated disorders |